Revolutionizing Medication with Vape-Like Devices: A Tough Road Ahead

Several North American companies such as Qnovia and MIIST Therapeutics are exploring vape-like devices to administer medication, potentially revolutionizing treatments for migraines and respiratory conditions like asthma. They face significant hurdles from health authorities and public perception. The goal is to prove efficacy and safety to make these devices a mainstream medical solution.

A number of North American companies are putting their bets on vape-like devices to treat conditions such as migraines and respiratory illnesses like asthma. These companies, including Qnovia and MIIST Therapeutics, have developed devices based on existing medical nebulisers, aiming to deliver medication more efficiently.

Qnovia and MIIST plan to introduce their devices initially as prescription-only nicotine replacement therapies. They face a challenging path as they strive to gain regulatory approval and combat the stigma or health concerns usually associated with vaping devices.

Despite the uphill battle, the companies are optimistic. Douglas Dunlap, the chief commercial officer at Greentank, believes that a faster delivery mechanism for treatments like migraines will be revolutionary. Yet, overcoming existing perceptions about vapes as medical devices remains a critical barrier.